As Washington considers limiting consumer pharmaceutical advertising, the industry tries to burnish its image.
When ex-Turing Pharmaceuticals CEO Martin Shkreli smirked his way through congressional testimony in February, refusing to answer questions about how his former company increased prices for Daraprim, a drug used to treat cancer and AIDS, by 5,000 percent, it (understandably) stoked Washington’s and the general public’s ire against the pharmaceutical industry. That same month, Congress introduced legislation to ban direct-to-consumer (DTC) drug ads. Not helping matters is this pugnacious election season that’s drawn stark contrasts to the broader issue of healthcare. In other words, the pharmaceutical industry finds itself in deep damage control mode. Pharma’s fight with Washington isn’t new, but according to industry experts, the industry’s efforts to restore its reputation have so far been lacking, and the battles with D.C. won’t end in the near term.
“The tobacco industry and the oil industry are probably the only two industries who have worse reputations than the pharmaceutical industry,” says John Mack, publisher and editor of Pharma Marketing News. “There’s no advertising on TV for the tobacco industry anymore, so I could see why there are calls to ban TV advertising for prescription drugs.”
Shkreli is the current poster boy for everything that’s wrong with the industry, but pharma’s battles with Washington date back at least to 1997, when regulatory changes by the FDA made DTC drug advertising more common in the United States. (The United States and New Zealand are the only two countries in the world that allow DTC advertising for prescription drugs, and total pharmaceutical ad spending in the U.S. rose to $4.9 billion in 2014 from $4.2 billion in 2013, according to Kantar Media.)
Esta historia es de la edición March 28, 2016 de ADWEEK.
Comience su prueba gratuita de Magzter GOLD de 7 días para acceder a miles de historias premium seleccionadas y a más de 9,000 revistas y periódicos.
Ya eres suscriptor ? Conectar
Esta historia es de la edición March 28, 2016 de ADWEEK.
Comience su prueba gratuita de Magzter GOLD de 7 días para acceder a miles de historias premium seleccionadas y a más de 9,000 revistas y periódicos.
Ya eres suscriptor? Conectar
News Anchor Of The Year Megyn Kelly
From Trump to ailes, the fox news personality fearlessly faces off with the powers that be—and ends up crushing the cable ratings race.
The Big Bang
Global consultancies are rocking the agency world, creating a new universe of offerings that meld marketing and technology.
DROGA5
Using the fingers on just one hand, David Droga argues, you can count the number of agencies that possess a “strong soul.”
Ogily
When it comes to leadership changes, 2016 will be remembered as a time of disruption.
The Myth of White Space
'Brands have to stand out in an obvious crowd—not stand alone in an unusual spot that no one cares about.'
Brand Phelps
Can the greatest olympian in history be as dominant out of the pool as he was in it?
Masters Of Their Domain
WHY DIGITAL BRANDS ARE KILLING IT IN ECOMMERCE. BY LAUREN JOHNSON
Winners' Playbook
BRANDS OFTEN FIND THAT WHEN THEY AIM TO DO GOOD, THEY ALSO END UP DOING WELL. HERE ARE FOUR RULES TO KEEP IN MIND. BY DAN TYNAN
Flipping The Disruption Script
THE FORTUNE 500 SHOULDN’T REST ON THEIR LAURELS OF HAVING A FIRST-TO- MARKET ADVANTAGE.
MCCann
All things old were new again in 2017 as McCann dominated the U.S. agency landscape with a string of wins and created the most-discussed campaign of the year in Fearless Girl.